Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cel-Sci Corporation CVM

Healthcare  —  Biotechnology
1.67 (0.05) (2.91%) as of 25 Sep
Market cap
$30.3M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cel-Sci Corporation (CVM) Business Profile

Updated before January 2025

Company Overview

Cel-Sci Corporation (CVM) is a biotechnology company that was founded in 1983 and is headquartered in Vienna, Virginia, USA. The company specializes in the research and development of immunotherapy products for the treatment of cancer, infectious diseases, and autoimmune disorders. Cel-Sci is publicly traded on the NYSE American under the ticker symbol CVM. The company is led by Geert Kersten, who has served as the Chief Executive Officer since 1995. Kersten has been instrumental in steering the company’s strategic direction and advancing its flagship product, Multikine® (Leukocyte Interleukin, Injection), through clinical trials. Other key members of the leadership team include Eyal Talor, Ph.D., Chief Scientific Officer, and Patricia Prichep, Senior Vice President of Operations.

Core Business Segments

Cel-Sci Corporation focuses on the development of immunotherapy-based treatments, with its primary emphasis on oncology and infectious diseases. The company’s core business segments include:

1. Oncology

  • Multikine® (Leukocyte Interleukin, Injection): This is Cel-Sci’s flagship product and is designed to be used as a first-line immunotherapy for head and neck cancer. Multikine is intended to enhance the body’s immune response to tumors before standard treatments like surgery, radiation, or chemotherapy are administered. The product has completed a pivotal Phase III clinical trial, which is one of the largest studies conducted for head and neck cancer.

2. Infectious Diseases

  • LEAPS (Ligand Epitope Antigen Presentation System): This is a proprietary platform technology that aims to develop vaccines and treatments for infectious diseases, including COVID-19, H1N1, and other viral infections. LEAPS is designed to stimulate a targeted immune response by combining T-cell binding ligands with disease-specific antigens.

3. Autoimmune Disorders

  • Cel-Sci is also exploring the potential of its LEAPS platform to address autoimmune diseases by modulating the immune system to reduce inflammation and tissue damage.

Business Model

Cel-Sci’s business model revolves around the development and commercialization of innovative immunotherapy products. The company primarily generates revenue through licensing agreements, partnerships, and potential future product sales. Key aspects of its business model include:

  • Research and Development (R&D): Cel-Sci invests heavily in R&D to advance its pipeline of immunotherapy products. The company collaborates with academic institutions, research organizations, and contract research organizations (CROs) to conduct clinical trials and preclinical studies.
  • Regulatory Approvals: A significant portion of Cel-Sci’s efforts is focused on obtaining regulatory approvals for its products from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • Partnerships and Licensing: Cel-Sci seeks strategic partnerships with pharmaceutical companies to co-develop and commercialize its products. These partnerships provide funding and expertise to accelerate product development.
  • Manufacturing: The company operates its own manufacturing facility in Maryland, USA, which is designed to produce Multikine and other immunotherapy products in compliance with Good Manufacturing Practices (GMP).

Strategic Direction

Cel-Sci Corporation’s strategic direction is centered on advancing its pipeline of immunotherapy products and expanding its market presence. Key elements of its strategy include:

  • Commercialization of Multikine: The company aims to secure regulatory approvals for Multikine and bring it to market as a first-line treatment for head and neck cancer. This is expected to be a major revenue driver for Cel-Sci.
  • Expansion of LEAPS Platform: Cel-Sci plans to further develop its LEAPS technology for use in vaccines and treatments for infectious diseases and autoimmune disorders. The company is exploring partnerships to accelerate the development of LEAPS-based products.
  • Global Market Penetration: Cel-Sci is focused on expanding its presence in international markets by seeking regulatory approvals in regions such as Europe, Asia, and Latin America.
  • Sustainability Goals: While Cel-Sci has not explicitly outlined sustainability goals, the company is committed to ethical practices in clinical research and manufacturing.

Competitive Landscape

Cel-Sci operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Bristol-Myers Squibb: Known for its immunotherapy products like Opdivo and Yervoy, which are used to treat various cancers.
  • Merck & Co.: A leader in oncology with its blockbuster drug Keytruda, an immune checkpoint inhibitor.
  • Roche: Offers a range of cancer immunotherapy products, including Tecentriq.
  • Smaller Biotech Firms: Companies like Inovio Pharmaceuticals and Novavax are also developing immunotherapy and vaccine technologies that could compete with Cel-Sci’s LEAPS platform.

Risk Factors

Cel-Sci faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: The approval process for new drugs is lengthy and uncertain. Delays or rejections by regulatory agencies could hinder the commercialization of Multikine and other products.
  • Market Dependence: The company’s success is heavily reliant on the approval and market adoption of Multikine. Failure to achieve commercial success with this product could significantly impact revenue.
  • Supply Chain Disruptions: Cel-Sci’s reliance on third-party suppliers for raw materials and components poses a risk of supply chain disruptions.
  • Financial Risks: As a development-stage company, Cel-Sci has a history of operating losses and may require additional funding to sustain its operations.
  • Competition: The biotechnology sector is highly competitive, and Cel-Sci may face challenges in differentiating its products from those of larger, more established competitors.

Recent Developments

  • Phase III Clinical Trial Results: Cel-Sci recently announced the completion of its pivotal Phase III clinical trial for Multikine, which demonstrated promising results in improving overall survival rates for head and neck cancer patients.
  • COVID-19 Vaccine Development: The company has been leveraging its LEAPS platform to develop a potential vaccine for COVID-19. Preclinical studies have shown encouraging results.
  • Manufacturing Facility Expansion: Cel-Sci has expanded its manufacturing facility to increase production capacity for Multikine and other pipeline products.
  • Partnerships: The company has entered into collaborations with academic institutions and research organizations to advance its R&D efforts.

Investment Considerations

Strengths:

  • Innovative Pipeline: Cel-Sci’s focus on immunotherapy positions it at the forefront of cutting-edge medical research.
  • Strong Leadership: The company’s experienced management team has a proven track record in advancing clinical programs.
  • Market Potential: The global oncology market is expected to grow significantly, providing opportunities for Multikine and other products.
  • Proprietary Technology: The LEAPS platform offers a unique approach to vaccine and immunotherapy development.

Risks:

  • Regulatory Uncertainty: The approval process for new drugs is inherently risky and time-consuming.
  • Financial Instability: Cel-Sci’s reliance on external funding could pose challenges if additional capital is not secured.
  • Market Competition: The company faces intense competition from larger pharmaceutical firms with established products.

Conclusion

Cel-Sci Corporation is a pioneering biotechnology company with a strong focus on immunotherapy for cancer and infectious diseases. While the company faces significant risks, its innovative pipeline, proprietary technology, and experienced leadership position it as a potential leader in the biotech sector. With the anticipated commercialization of Multikine and the expansion of its LEAPS platform, Cel-Sci is well-positioned for future growth. However, investors should carefully consider the regulatory and financial risks associated with investing in a development-stage biotech company.